These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 23378772)
101. Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA. Chen J; Guo XZ; Li HY; Liu X; Ren LN; Wang D; Zhao JJ Vaccine; 2013 Sep; 31(41):4585-90. PubMed ID: 23928463 [TBL] [Abstract][Full Text] [Related]
102. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Merad M; Sathe P; Helft J; Miller J; Mortha A Annu Rev Immunol; 2013; 31():563-604. PubMed ID: 23516985 [TBL] [Abstract][Full Text] [Related]
103. Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer. Ni L Front Immunol; 2022; 13():887189. PubMed ID: 35619702 [TBL] [Abstract][Full Text] [Related]
104. What are the molecules involved in regulatory T-cells induction by dendritic cells in cancer? Ramos RN; de Moraes CJ; Zelante B; Barbuto JA Clin Dev Immunol; 2013; 2013():806025. PubMed ID: 23762097 [TBL] [Abstract][Full Text] [Related]
106. Dendritic cells fused with different pancreatic carcinoma cells induce different T-cell responses. Andoh Y; Makino N; Yamakawa M Onco Targets Ther; 2013; 6():29-40. PubMed ID: 23378772 [TBL] [Abstract][Full Text] [Related]
107. Effect of insulin on functional status of cord blood-derived dendritic cells and on dendritic cell-induced CTL cytotoxicity against pancreatic cancer cell lines. Liu QL; Wang YS; Wang JX Hepatobiliary Pancreat Dis Int; 2009 Oct; 8(5):529-34. PubMed ID: 19822498 [TBL] [Abstract][Full Text] [Related]
108. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639 [TBL] [Abstract][Full Text] [Related]
110. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer Chen J; Guo XZ; Li HY; Zhao JJ; Xu WD World J Gastroenterol; 2017 Feb; 23(5):817-829. PubMed ID: 28223726 [TBL] [Abstract][Full Text] [Related]
111. Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect. Kasuya K; Nagakawa Y; Suzuki M; Tanaka H; Ohta H; Itoi T; Tsuchida A Exp Ther Med; 2011 Nov; 2(6):1047-1052. PubMed ID: 22977618 [TBL] [Abstract][Full Text] [Related]
112. The role of 1α,25-dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3+ and IL-10+ CD4+ T cells. Urry Z; Chambers ES; Xystrakis E; Dimeloe S; Richards DF; Gabryšová L; Christensen J; Gupta A; Saglani S; Bush A; O'Garra A; Brown Z; Hawrylowicz CM Eur J Immunol; 2012 Oct; 42(10):2697-708. PubMed ID: 22903229 [TBL] [Abstract][Full Text] [Related]
113. Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes. Bernal M; Ruiz-Cabello F; Concha A; Paschen A; Garrido F Cancer Immunol Immunother; 2012 Sep; 61(9):1359-71. PubMed ID: 22833104 [TBL] [Abstract][Full Text] [Related]
114. Clinical evaluation of dendritic cells vaccination for advanced cancer patients at Fukushima Medical University. Nakamura I; Kanazawa M; Sato Y; Irisawa A; Takagi T; Ogata T; Kashimura S; Kenjo A; Suzuki H; Shibata M; Shimura T; Ohira H; Goto M; Takenoshita S; Ohto H Fukushima J Med Sci; 2012; 58(1):40-8. PubMed ID: 22790891 [TBL] [Abstract][Full Text] [Related]
115. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Le DT; Jaffee EM Cancer Res; 2012 Jul; 72(14):3439-44. PubMed ID: 22761338 [TBL] [Abstract][Full Text] [Related]
116. Investigation of a new tumor-associated glycosylated antigen as target for dendritic cell vaccination in pancreatic cancer. Béraud E; Collignon A; Franceschi C; Olive D; Lombardo D; Mas E Oncoimmunology; 2012 Jan; 1(1):56-61. PubMed ID: 22720212 [TBL] [Abstract][Full Text] [Related]